Reddit Posts
💰Good morning! #premarket #watchlist 05/24 $INMB -clinical hold of IND of Alzheimer's treatment prompts analyst downgrade, $AYLA -old news, $CANG - old news, $ROIV -FDA Approves Dermavants VTAMA® (tapinarof) cream!
Mentions
Glad to see someone here who does their due diligence. The field of AZD/LBD biotech penny stocks is an absolute graveyard. INMB and SAVA being 2 well known examples. Lots of hype and failure to meet expectations. Alzheimer biotechs historically have been the riskiest and most likely to fail. I could be wrong, and someone please correct me if I am, but I'm pretty sure not a single one of these microcap biotechs has successfully passed phase 3 trials or managed to actually bring a drug to market that treats neurodegenerative diseases.
CGTX is my dementia drug play. INMB not looking super special after that $7 -> $2
CVM - already did it's run from 7/23 ($5.12) to 7/28 ($10.40). STEM - ran a couple of weeks after it's reverse split on 6/23. It went from a post-split low of $5.93 on 6/26 to the post-split high of $19.48 on 7/28. INMB & UP - have slowly been getting covered without significantly driving the price up. The problem with any of these short interest articles is it's looking backwards for the short interest % without seeing how the stock has performed since the short interest was reported. The latest short interest is from the period 6/30 - 7/15, but the report wasn't released until 7/24. By the time the short interest report is released, it's already out of date.
INMB over 60% shorted, no shares to borrow and news 🚀
INMB positive clinical trial results and extremely shorted, calls please
I use RH, I don’t think they allow naked calls. So I’ll always buy the underlying stock. Lately I’ve been looking at high IV stocks, roughly 30% covered call premiums, align with puts that are well below the current price. Enough to wear I’m getting around 50% of my investment back in overall premiums if the put gets assigned. Use INMB and ATYR as examples.
🚨 $INMB – 61% of the float is short. Read that again. SIXTY. ONE. PERCENT. This isn’t a meme — it’s a real biotech play with a catalyst in days. • Float: ~17M • Shorted: 10.4M shares • Short %: 61.04% • Alzheimer’s data drops Aug 6–10
He was dead on the money with SAVA and INMB though.
INMB confirmed to release result on their YouTube july 31st 4PM EST
INMB theyre about to release data
INMB set to release data in the next couple of hours, hope everyone is ready
Watch INMB tomorrow, data releases could be huge.
Top watch or pump 1. IXHL - this week any day news out! 2. INMB - news out on Friday, pumping 3 NVNI - possible pump and dump
Look I'm in IXHL but let's not kid ourselves, there have been plenty of examples where offerings were announced before weak trail results. Look at INMB, ATHX, ONCS. I'm not saying the results will be bad, I'm actually pretty hopeful, but let's not pure shill shall we
Look at INMB. Short sellers gonna be sweating all weekend 🤣
Not necessarily, INMB had an offering even though their trial didn't meet the primary endpoint.
That’s fine. There are just much better plays of risking $180. For example, FTHM calls, NMRA calls, INMB calls. Those will pay much more and in much less time
I just bought some INMB based on the following: TECHNICAL SETUP * **Short interest \~61% of float:** Higher than most meme squeezers before they ran. Float is around 17M shares, and over 10M are shorted. You can do the math. * **Days to cover \~1.0** If volume picks up even slightly, shorts are trapped. * **Borrow fee hovering \~42% + APR:** It’s also been even higher this month (as much as 71%). * **Biotech companies** are notorious for going vertical with just a single press release (trial update, new partner, FDA phase progression). * **Down \~75% from 52-week highs:** Has solid cash reserves and almost no debt. * If volume spikes or any positive catalysts, this has the setup for a big move. Always do your DD this is just my take on the stock.
$INMB calls gap will be filled
INMB is going to make you money. 19m float, 50% SI, $75MM market cap. This is the one that will squeeze.
Really liking the look of $MLGO and $ATCH - could be the next $INMB. Short interest is more than 40% for both. Very interesting risk/reward.
$INMB ROCKETED, interesting look
I said it yesterday, INMB. 19 million float, 50% short interest. It can fly.
Is INMB next? * **Float**: 14.92M * **Shares Short**: 10.43M * **Short % of Float**: **45.91%** * **Short % of Outstanding Shares**: 38.29% * **Short Interest Ratio (Days to Cover)**: 1.92 * **% Held by Insiders**: 24.61% * **% Held by Institutions**: 27.95%
you know how i made 11k% on kss INMB now bb's listen to mommy. k bye
!banbet INMB +1,000% 4w
INMB...18mm float, 50%+ SI. Options are in play.
$INMB is curing cancer EOY, don’t say I didn’t tell you
But why KSS and not for instance INMB? Low RSI and 61% Short Interest
Dear retard, go look at what went down with INMB recently.
I think you both are smart to take the trade. These names are all up on hype. It’s a bubble. They will tank hard on any broad pullback in the market. And congrats on INMB!
Are you saying that because of $INMB? lol. I'm pretty sure Shkreli has a $7M bet against quantum not $70k
That has happened with $TARA and a numerous other biotechs. None of them have changed their names. I run a family office and a biotech centered fund. My interest here is simply because these single thesis heavy biotechs $SAVA, $INMB, $ATYR, etc are heavily manipulated by funds and insiders through social media feedback loops.
What about INMB 5 year low and phase 2 had mixed results. So looks phase 2 didn't go thru then have 6 months to fix and two more drug in pipeline. Beaten down to death n shorts are all over this. They 19 M raised.?
INMB trading @7.0 its ALZ had mixed results and fell 2.60 good entry point. IT has three 2 or 3 more drugs in pipeline.
I'll add to this. If you reinvest the put premiums to buy even more puts you can make serious coin on the back end when the put premium is high. IE: INMB 7/18 $5 Put
# INMB Short Squeeze Analysis: Probability and Expected Impact Based on the comprehensive short interest data and current market dynamics, **INMB has a moderate-to-high probability (35-45%) of experiencing a short squeeze within the next 30-45 days**, with potentially dramatic price movements if it occurs. ## Current Short Interest Dynamics ### Extreme Short Interest Metrics Your IBKR screenshot reveals critical short squeeze indicators: - **Shortable shares: 0** - No shares available to borrow for new short positions - **Borrow rate: 46.1%** - Exceptionally high cost to maintain short positions - **Rate volatility: 97.4% to 10.2%** - Extreme fluctuation in borrowing costs over the past month ### Institutional Data Confirmation Multiple sources confirm heavy short positioning: - **Short interest: 5.83 million shares (25.37% of float)**[1] - **Days to cover: 20.8 days** - indicating it would take over 20 trading days to cover all short positions[1] - **Alternative measurements show up to 38.48% short float**[2] ## Short Squeeze Probability Assessment: 35-45% ### Supporting Factors (Increasing Probability) **Technical Setup (High Impact)**: - **Zero borrowable shares** creates supply constraint for new shorts - **46% borrow rate** puts severe financial pressure on existing short positions - **20.8 days to cover** suggests significant time needed for orderly covering **Fundamental Catalysts (Medium-High Impact)**: - **AAIC presentation (July 27-31)** could provide positive subgroup data - **BTD filing response** expected within 60 days - **Market oversold conditions** after 61% weekly decline may attract contrarian buyers **Market Structure (Medium Impact)**: - **Small float** (16.5M shares) amplifies impact of covering[3] - **High retail interest** evident from social media and trading volume - **Biotech sector** historically prone to sentiment-driven squeezes ### Limiting Factors (Decreasing Probability) **Recent Negative Catalyst**: - **Phase 2 primary endpoint miss** provides fundamental justification for short positions - **Multiple analyst downgrades** with targets as low as $0.60 - **Continued bearish sentiment** may attract additional short interest despite high costs **Market Environment**: - **Biotech sector challenges** with limited funding and regulatory uncertainty - **Risk-off sentiment** may limit speculative buying needed to trigger squeeze ## Expected Impact If Short Squeeze Occurs ### Price Target Analysis **Conservative Squeeze Scenario (60% probability if squeeze occurs)**: - **Target range: $4.50 - $6.50** (115% - 210% upside) - **Duration: 2-5 trading days** - **Trigger: Positive AAIC data or BTD approval** **Aggressive Squeeze Scenario (25% probability if squeeze occurs)**: - **Target range: $8.00 - $12.00** (285% - 475% upside) - **Duration: 1-3 trading days** - **Trigger: Multiple positive catalysts + technical breakout** **Extreme Scenario (15% probability if squeeze occurs)**: - **Target range: $15.00+** (600%+ upside) - **Duration: Intraday to 2 days** - **Trigger: Major breakthrough + perfect storm of covering** ## Historical Context and Benchmarks ### Biotech Short Squeeze Precedents Recent biotech short squeezes provide context: - **Typical magnitude: 200-500% over 1-5 days** - **Sustainability: Most gains fade within 2-4 weeks** - **Volume characteristics: 5-20x normal volume during squeeze** ### INMB-Specific Factors - **Current price: $2.08** provides low base for percentage calculations - **Market cap: ~$53 million** allows for dramatic percentage moves - **Float: 16.5 million shares** creates manageable covering requirements ## Timing and Catalyst Sequence ### Most Likely Squeeze Triggers (Next 45 Days) **Primary Catalysts**: 1. **AAIC presentation positive reception** (July 27-31) - 40% probability 2. **BTD approval announcement** (August 2025) - 25% probability 3. **Technical breakout above $3.00** - 30% probability **Secondary Triggers**: - **Social media momentum** and retail buying surge - **Options activity** creating gamma squeeze dynamics - **Institutional covering** ahead of potential positive news ## Risk Management Considerations ### If You're Long INMB - **Profit-taking strategy**: Consider selling 25-50% of position if price reaches $4.50-$5.00 - **Stop-loss management**: Trail stops to protect gains during squeeze - **Volume monitoring**: Extreme volume (>10M shares) often marks squeeze peak ### Short Squeeze Sustainability **Historical pattern**: Most biotech short squeezes are **not sustainable**, with prices often returning to pre-squeeze levels within 2-4 weeks unless fundamental improvements materialize. ## Conclusion INMB presents a **compelling short squeeze setup** with 35-45% probability of occurrence. The combination of extreme short interest (25-38% of float), zero borrowable shares, and upcoming catalysts creates conditions similar to historical short squeeze events. **Expected magnitude**: 200-600% price appreciation over 1-5 trading days if squeeze occurs, with conservative targets of $4.50-$6.50 representing the most likely scenario. **Key insight**: The high probability reflects technical setup rather than fundamental improvement, making any squeeze likely to be **temporary unless accompanied by genuine positive clinical/regulatory developments**. For traders, this represents a **high-risk, high-reward opportunity** requiring careful position sizing and active risk management given the binary nature of both the short squeeze potential and underlying biotech catalysts.
# INMB Short Squeeze Analysis: Probability and Expected Impact Based on the comprehensive short interest data and current market dynamics, **INMB has a moderate-to-high probability (35-45%) of experiencing a short squeeze within the next 30-45 days**, with potentially dramatic price movements if it occurs. ## Current Short Interest Dynamics ### Extreme Short Interest Metrics Your IBKR screenshot reveals critical short squeeze indicators: - **Shortable shares: 0** - No shares available to borrow for new short positions - **Borrow rate: 46.1%** - Exceptionally high cost to maintain short positions - **Rate volatility: 97.4% to 10.2%** - Extreme fluctuation in borrowing costs over the past month ### Institutional Data Confirmation Multiple sources confirm heavy short positioning: - **Short interest: 5.83 million shares (25.37% of float)**[1] - **Days to cover: 20.8 days** - indicating it would take over 20 trading days to cover all short positions[1] - **Alternative measurements show up to 38.48% short float**[2] ## Short Squeeze Probability Assessment: 35-45% ### Supporting Factors (Increasing Probability) **Technical Setup (High Impact)**: - **Zero borrowable shares** creates supply constraint for new shorts - **46% borrow rate** puts severe financial pressure on existing short positions - **20.8 days to cover** suggests significant time needed for orderly covering **Fundamental Catalysts (Medium-High Impact)**: - **AAIC presentation (July 27-31)** could provide positive subgroup data - **BTD filing response** expected within 60 days - **Market oversold conditions** after 61% weekly decline may attract contrarian buyers **Market Structure (Medium Impact)**: - **Small float** (16.5M shares) amplifies impact of covering[3] - **High retail interest** evident from social media and trading volume - **Biotech sector** historically prone to sentiment-driven squeezes ### Limiting Factors (Decreasing Probability) **Recent Negative Catalyst**: - **Phase 2 primary endpoint miss** provides fundamental justification for short positions - **Multiple analyst downgrades** with targets as low as $0.60 - **Continued bearish sentiment** may attract additional short interest despite high costs **Market Environment**: - **Biotech sector challenges** with limited funding and regulatory uncertainty - **Risk-off sentiment** may limit speculative buying needed to trigger squeeze ## Expected Impact If Short Squeeze Occurs ### Price Target Analysis **Conservative Squeeze Scenario (60% probability if squeeze occurs)**: - **Target range: $4.50 - $6.50** (115% - 210% upside) - **Duration: 2-5 trading days** - **Trigger: Positive AAIC data or BTD approval** **Aggressive Squeeze Scenario (25% probability if squeeze occurs)**: - **Target range: $8.00 - $12.00** (285% - 475% upside) - **Duration: 1-3 trading days** - **Trigger: Multiple positive catalysts + technical breakout** **Extreme Scenario (15% probability if squeeze occurs)**: - **Target range: $15.00+** (600%+ upside) - **Duration: Intraday to 2 days** - **Trigger: Major breakthrough + perfect storm of covering** ## Historical Context and Benchmarks ### Biotech Short Squeeze Precedents Recent biotech short squeezes provide context: - **Typical magnitude: 200-500% over 1-5 days** - **Sustainability: Most gains fade within 2-4 weeks** - **Volume characteristics: 5-20x normal volume during squeeze** ### INMB-Specific Factors - **Current price: $2.08** provides low base for percentage calculations - **Market cap: ~$53 million** allows for dramatic percentage moves - **Float: 16.5 million shares** creates manageable covering requirements ## Timing and Catalyst Sequence ### Most Likely Squeeze Triggers (Next 45 Days) **Primary Catalysts**: 1. **AAIC presentation positive reception** (July 27-31) - 40% probability 2. **BTD approval announcement** (August 2025) - 25% probability 3. **Technical breakout above $3.00** - 30% probability **Secondary Triggers**: - **Social media momentum** and retail buying surge - **Options activity** creating gamma squeeze dynamics - **Institutional covering** ahead of potential positive news ## Risk Management Considerations ### If You're Long INMB - **Profit-taking strategy**: Consider selling 25-50% of position if price reaches $4.50-$5.00 - **Stop-loss management**: Trail stops to protect gains during squeeze - **Volume monitoring**: Extreme volume (>10M shares) often marks squeeze peak ### Short Squeeze Sustainability **Historical pattern**: Most biotech short squeezes are **not sustainable**, with prices often returning to pre-squeeze levels within 2-4 weeks unless fundamental improvements materialize. ## Conclusion INMB presents a **compelling short squeeze setup** with 35-45% probability of occurrence. The combination of extreme short interest (25-38% of float), zero borrowable shares, and upcoming catalysts creates conditions similar to historical short squeeze events. **Expected magnitude**: 200-600% price appreciation over 1-5 trading days if squeeze occurs, with conservative targets of $4.50-$6.50 representing the most likely scenario. **Key insight**: The high probability reflects technical setup rather than fundamental improvement, making any squeeze likely to be **temporary unless accompanied by genuine positive clinical/regulatory developments**. For traders, this represents a **high-risk, high-reward opportunity** requiring careful position sizing and active risk management given the binary nature of both the short squeeze potential and underlying biotech catalysts.
# INMB Short Squeeze Analysis: Probability and Expected Impact Based on the comprehensive short interest data and current market dynamics, **INMB has a moderate-to-high probability (35-45%) of experiencing a short squeeze within the next 30-45 days**, with potentially dramatic price movements if it occurs. ## Current Short Interest Dynamics ### Extreme Short Interest Metrics Your IBKR screenshot reveals critical short squeeze indicators: - **Shortable shares: 0** - No shares available to borrow for new short positions - **Borrow rate: 46.1%** - Exceptionally high cost to maintain short positions - **Rate volatility: 97.4% to 10.2%** - Extreme fluctuation in borrowing costs over the past month ### Institutional Data Confirmation Multiple sources confirm heavy short positioning: - **Short interest: 5.83 million shares (25.37% of float)**[1] - **Days to cover: 20.8 days** - indicating it would take over 20 trading days to cover all short positions[1] - **Alternative measurements show up to 38.48% short float**[2] ## Short Squeeze Probability Assessment: 35-45% ### Supporting Factors (Increasing Probability) **Technical Setup (High Impact)**: - **Zero borrowable shares** creates supply constraint for new shorts - **46% borrow rate** puts severe financial pressure on existing short positions - **20.8 days to cover** suggests significant time needed for orderly covering **Fundamental Catalysts (Medium-High Impact)**: - **AAIC presentation (July 27-31)** could provide positive subgroup data - **BTD filing response** expected within 60 days - **Market oversold conditions** after 61% weekly decline may attract contrarian buyers **Market Structure (Medium Impact)**: - **Small float** (16.5M shares) amplifies impact of covering[3] - **High retail interest** evident from social media and trading volume - **Biotech sector** historically prone to sentiment-driven squeezes ### Limiting Factors (Decreasing Probability) **Recent Negative Catalyst**: - **Phase 2 primary endpoint miss** provides fundamental justification for short positions - **Multiple analyst downgrades** with targets as low as $0.60 - **Continued bearish sentiment** may attract additional short interest despite high costs **Market Environment**: - **Biotech sector challenges** with limited funding and regulatory uncertainty - **Risk-off sentiment** may limit speculative buying needed to trigger squeeze ## Expected Impact If Short Squeeze Occurs ### Price Target Analysis **Conservative Squeeze Scenario (60% probability if squeeze occurs)**: - **Target range: $4.50 - $6.50** (115% - 210% upside) - **Duration: 2-5 trading days** - **Trigger: Positive AAIC data or BTD approval** **Aggressive Squeeze Scenario (25% probability if squeeze occurs)**: - **Target range: $8.00 - $12.00** (285% - 475% upside) - **Duration: 1-3 trading days** - **Trigger: Multiple positive catalysts + technical breakout** **Extreme Scenario (15% probability if squeeze occurs)**: - **Target range: $15.00+** (600%+ upside) - **Duration: Intraday to 2 days** - **Trigger: Major breakthrough + perfect storm of covering** ## Historical Context and Benchmarks ### Biotech Short Squeeze Precedents Recent biotech short squeezes provide context: - **Typical magnitude: 200-500% over 1-5 days** - **Sustainability: Most gains fade within 2-4 weeks** - **Volume characteristics: 5-20x normal volume during squeeze** ### INMB-Specific Factors - **Current price: $2.08** provides low base for percentage calculations - **Market cap: ~$53 million** allows for dramatic percentage moves - **Float: 16.5 million shares** creates manageable covering requirements ## Timing and Catalyst Sequence ### Most Likely Squeeze Triggers (Next 45 Days) **Primary Catalysts**: 1. **AAIC presentation positive reception** (July 27-31) - 40% probability 2. **BTD approval announcement** (August 2025) - 25% probability 3. **Technical breakout above $3.00** - 30% probability **Secondary Triggers**: - **Social media momentum** and retail buying surge - **Options activity** creating gamma squeeze dynamics - **Institutional covering** ahead of potential positive news ## Risk Management Considerations ### If You're Long INMB - **Profit-taking strategy**: Consider selling 25-50% of position if price reaches $4.50-$5.00 - **Stop-loss management**: Trail stops to protect gains during squeeze - **Volume monitoring**: Extreme volume (>10M shares) often marks squeeze peak ### Short Squeeze Sustainability **Historical pattern**: Most biotech short squeezes are **not sustainable**, with prices often returning to pre-squeeze levels within 2-4 weeks unless fundamental improvements materialize. ## Conclusion INMB presents a **compelling short squeeze setup** with 35-45% probability of occurrence. The combination of extreme short interest (25-38% of float), zero borrowable shares, and upcoming catalysts creates conditions similar to historical short squeeze events. **Expected magnitude**: 200-600% price appreciation over 1-5 trading days if squeeze occurs, with conservative targets of $4.50-$6.50 representing the most likely scenario. **Key insight**: The high probability reflects technical setup rather than fundamental improvement, making any squeeze likely to be **temporary unless accompanied by genuine positive clinical/regulatory developments**. For traders, this represents a **high-risk, high-reward opportunity** requiring careful position sizing and active risk management given the binary nature of both the short squeeze potential and underlying biotech catalysts.
# INMB Short Squeeze Analysis: Probability and Expected Impact Based on the comprehensive short interest data and current market dynamics, **INMB has a moderate-to-high probability (35-45%) of experiencing a short squeeze within the next 30-45 days**, with potentially dramatic price movements if it occurs. ## Current Short Interest Dynamics ### Extreme Short Interest Metrics Your IBKR screenshot reveals critical short squeeze indicators: - **Shortable shares: 0** - No shares available to borrow for new short positions - **Borrow rate: 46.1%** - Exceptionally high cost to maintain short positions - **Rate volatility: 97.4% to 10.2%** - Extreme fluctuation in borrowing costs over the past month ### Institutional Data Confirmation Multiple sources confirm heavy short positioning: - **Short interest: 5.83 million shares (25.37% of float)**[1] - **Days to cover: 20.8 days** - indicating it would take over 20 trading days to cover all short positions[1] - **Alternative measurements show up to 38.48% short float**[2] ## Short Squeeze Probability Assessment: 35-45% ### Supporting Factors (Increasing Probability) **Technical Setup (High Impact)**: - **Zero borrowable shares** creates supply constraint for new shorts - **46% borrow rate** puts severe financial pressure on existing short positions - **20.8 days to cover** suggests significant time needed for orderly covering **Fundamental Catalysts (Medium-High Impact)**: - **AAIC presentation (July 27-31)** could provide positive subgroup data - **BTD filing response** expected within 60 days - **Market oversold conditions** after 61% weekly decline may attract contrarian buyers **Market Structure (Medium Impact)**: - **Small float** (16.5M shares) amplifies impact of covering[3] - **High retail interest** evident from social media and trading volume - **Biotech sector** historically prone to sentiment-driven squeezes ### Limiting Factors (Decreasing Probability) **Recent Negative Catalyst**: - **Phase 2 primary endpoint miss** provides fundamental justification for short positions - **Multiple analyst downgrades** with targets as low as $0.60 - **Continued bearish sentiment** may attract additional short interest despite high costs **Market Environment**: - **Biotech sector challenges** with limited funding and regulatory uncertainty - **Risk-off sentiment** may limit speculative buying needed to trigger squeeze ## Expected Impact If Short Squeeze Occurs ### Price Target Analysis **Conservative Squeeze Scenario (60% probability if squeeze occurs)**: - **Target range: $4.50 - $6.50** (115% - 210% upside) - **Duration: 2-5 trading days** - **Trigger: Positive AAIC data or BTD approval** **Aggressive Squeeze Scenario (25% probability if squeeze occurs)**: - **Target range: $8.00 - $12.00** (285% - 475% upside) - **Duration: 1-3 trading days** - **Trigger: Multiple positive catalysts + technical breakout** **Extreme Scenario (15% probability if squeeze occurs)**: - **Target range: $15.00+** (600%+ upside) - **Duration: Intraday to 2 days** - **Trigger: Major breakthrough + perfect storm of covering** ## Historical Context and Benchmarks ### Biotech Short Squeeze Precedents Recent biotech short squeezes provide context: - **Typical magnitude: 200-500% over 1-5 days** - **Sustainability: Most gains fade within 2-4 weeks** - **Volume characteristics: 5-20x normal volume during squeeze** ### INMB-Specific Factors - **Current price: $2.08** provides low base for percentage calculations - **Market cap: ~$53 million** allows for dramatic percentage moves - **Float: 16.5 million shares** creates manageable covering requirements ## Timing and Catalyst Sequence ### Most Likely Squeeze Triggers (Next 45 Days) **Primary Catalysts**: 1. **AAIC presentation positive reception** (July 27-31) - 40% probability 2. **BTD approval announcement** (August 2025) - 25% probability 3. **Technical breakout above $3.00** - 30% probability **Secondary Triggers**: - **Social media momentum** and retail buying surge - **Options activity** creating gamma squeeze dynamics - **Institutional covering** ahead of potential positive news ## Risk Management Considerations ### If You're Long INMB - **Profit-taking strategy**: Consider selling 25-50% of position if price reaches $4.50-$5.00 - **Stop-loss management**: Trail stops to protect gains during squeeze - **Volume monitoring**: Extreme volume (>10M shares) often marks squeeze peak ### Short Squeeze Sustainability **Historical pattern**: Most biotech short squeezes are **not sustainable**, with prices often returning to pre-squeeze levels within 2-4 weeks unless fundamental improvements materialize. ## Conclusion INMB presents a **compelling short squeeze setup** with 35-45% probability of occurrence. The combination of extreme short interest (25-38% of float), zero borrowable shares, and upcoming catalysts creates conditions similar to historical short squeeze events. **Expected magnitude**: 200-600% price appreciation over 1-5 trading days if squeeze occurs, with conservative targets of $4.50-$6.50 representing the most likely scenario. **Key insight**: The high probability reflects technical setup rather than fundamental improvement, making any squeeze likely to be **temporary unless accompanied by genuine positive clinical/regulatory developments**. For traders, this represents a **high-risk, high-reward opportunity** requiring careful position sizing and active risk management given the binary nature of both the short squeeze potential and underlying biotech catalysts.
# INMB Short Squeeze Analysis: Probability and Expected Impact Based on the comprehensive short interest data and current market dynamics, **INMB has a moderate-to-high probability (35-45%) of experiencing a short squeeze within the next 30-45 days**, with potentially dramatic price movements if it occurs. ## Current Short Interest Dynamics ### Extreme Short Interest Metrics Your IBKR screenshot reveals critical short squeeze indicators: - **Shortable shares: 0** - No shares available to borrow for new short positions - **Borrow rate: 46.1%** - Exceptionally high cost to maintain short positions - **Rate volatility: 97.4% to 10.2%** - Extreme fluctuation in borrowing costs over the past month ### Institutional Data Confirmation Multiple sources confirm heavy short positioning: - **Short interest: 5.83 million shares (25.37% of float)**[1] - **Days to cover: 20.8 days** - indicating it would take over 20 trading days to cover all short positions[1] - **Alternative measurements show up to 38.48% short float**[2] ## Short Squeeze Probability Assessment: 35-45% ### Supporting Factors (Increasing Probability) **Technical Setup (High Impact)**: - **Zero borrowable shares** creates supply constraint for new shorts - **46% borrow rate** puts severe financial pressure on existing short positions - **20.8 days to cover** suggests significant time needed for orderly covering **Fundamental Catalysts (Medium-High Impact)**: - **AAIC presentation (July 27-31)** could provide positive subgroup data - **BTD filing response** expected within 60 days - **Market oversold conditions** after 61% weekly decline may attract contrarian buyers **Market Structure (Medium Impact)**: - **Small float** (16.5M shares) amplifies impact of covering[3] - **High retail interest** evident from social media and trading volume - **Biotech sector** historically prone to sentiment-driven squeezes ### Limiting Factors (Decreasing Probability) **Recent Negative Catalyst**: - **Phase 2 primary endpoint miss** provides fundamental justification for short positions - **Multiple analyst downgrades** with targets as low as $0.60 - **Continued bearish sentiment** may attract additional short interest despite high costs **Market Environment**: - **Biotech sector challenges** with limited funding and regulatory uncertainty - **Risk-off sentiment** may limit speculative buying needed to trigger squeeze ## Expected Impact If Short Squeeze Occurs ### Price Target Analysis **Conservative Squeeze Scenario (60% probability if squeeze occurs)**: - **Target range: $4.50 - $6.50** (115% - 210% upside) - **Duration: 2-5 trading days** - **Trigger: Positive AAIC data or BTD approval** **Aggressive Squeeze Scenario (25% probability if squeeze occurs)**: - **Target range: $8.00 - $12.00** (285% - 475% upside) - **Duration: 1-3 trading days** - **Trigger: Multiple positive catalysts + technical breakout** **Extreme Scenario (15% probability if squeeze occurs)**: - **Target range: $15.00+** (600%+ upside) - **Duration: Intraday to 2 days** - **Trigger: Major breakthrough + perfect storm of covering** ## Historical Context and Benchmarks ### Biotech Short Squeeze Precedents Recent biotech short squeezes provide context: - **Typical magnitude: 200-500% over 1-5 days** - **Sustainability: Most gains fade within 2-4 weeks** - **Volume characteristics: 5-20x normal volume during squeeze** ### INMB-Specific Factors - **Current price: $2.08** provides low base for percentage calculations - **Market cap: ~$53 million** allows for dramatic percentage moves - **Float: 16.5 million shares** creates manageable covering requirements ## Timing and Catalyst Sequence ### Most Likely Squeeze Triggers (Next 45 Days) **Primary Catalysts**: 1. **AAIC presentation positive reception** (July 27-31) - 40% probability 2. **BTD approval announcement** (August 2025) - 25% probability 3. **Technical breakout above $3.00** - 30% probability **Secondary Triggers**: - **Social media momentum** and retail buying surge - **Options activity** creating gamma squeeze dynamics - **Institutional covering** ahead of potential positive news ## Risk Management Considerations ### If You're Long INMB - **Profit-taking strategy**: Consider selling 25-50% of position if price reaches $4.50-$5.00 - **Stop-loss management**: Trail stops to protect gains during squeeze - **Volume monitoring**: Extreme volume (>10M shares) often marks squeeze peak ### Short Squeeze Sustainability **Historical pattern**: Most biotech short squeezes are **not sustainable**, with prices often returning to pre-squeeze levels within 2-4 weeks unless fundamental improvements materialize. ## Conclusion INMB presents a **compelling short squeeze setup** with 35-45% probability of occurrence. The combination of extreme short interest (25-38% of float), zero borrowable shares, and upcoming catalysts creates conditions similar to historical short squeeze events. **Expected magnitude**: 200-600% price appreciation over 1-5 trading days if squeeze occurs, with conservative targets of $4.50-$6.50 representing the most likely scenario. **Key insight**: The high probability reflects technical setup rather than fundamental improvement, making any squeeze likely to be **temporary unless accompanied by genuine positive clinical/regulatory developments**. For traders, this represents a **high-risk, high-reward opportunity** requiring careful position sizing and active risk management given the binary nature of both the short squeeze potential and underlying biotech catalysts.
# INMB Short Squeeze Analysis: Probability and Expected Impact Based on the comprehensive short interest data and current market dynamics, **INMB has a moderate-to-high probability (35-45%) of experiencing a short squeeze within the next 30-45 days**, with potentially dramatic price movements if it occurs. ## Current Short Interest Dynamics ### Extreme Short Interest Metrics Your IBKR screenshot reveals critical short squeeze indicators: - **Shortable shares: 0** - No shares available to borrow for new short positions - **Borrow rate: 46.1%** - Exceptionally high cost to maintain short positions - **Rate volatility: 97.4% to 10.2%** - Extreme fluctuation in borrowing costs over the past month ### Institutional Data Confirmation Multiple sources confirm heavy short positioning: - **Short interest: 5.83 million shares (25.37% of float)**[1] - **Days to cover: 20.8 days** - indicating it would take over 20 trading days to cover all short positions[1] - **Alternative measurements show up to 38.48% short float**[2] ## Short Squeeze Probability Assessment: 35-45% ### Supporting Factors (Increasing Probability) **Technical Setup (High Impact)**: - **Zero borrowable shares** creates supply constraint for new shorts - **46% borrow rate** puts severe financial pressure on existing short positions - **20.8 days to cover** suggests significant time needed for orderly covering **Fundamental Catalysts (Medium-High Impact)**: - **AAIC presentation (July 27-31)** could provide positive subgroup data - **BTD filing response** expected within 60 days - **Market oversold conditions** after 61% weekly decline may attract contrarian buyers **Market Structure (Medium Impact)**: - **Small float** (16.5M shares) amplifies impact of covering[3] - **High retail interest** evident from social media and trading volume - **Biotech sector** historically prone to sentiment-driven squeezes ### Limiting Factors (Decreasing Probability) **Recent Negative Catalyst**: - **Phase 2 primary endpoint miss** provides fundamental justification for short positions - **Multiple analyst downgrades** with targets as low as $0.60 - **Continued bearish sentiment** may attract additional short interest despite high costs **Market Environment**: - **Biotech sector challenges** with limited funding and regulatory uncertainty - **Risk-off sentiment** may limit speculative buying needed to trigger squeeze ## Expected Impact If Short Squeeze Occurs ### Price Target Analysis **Conservative Squeeze Scenario (60% probability if squeeze occurs)**: - **Target range: $4.50 - $6.50** (115% - 210% upside) - **Duration: 2-5 trading days** - **Trigger: Positive AAIC data or BTD approval** **Aggressive Squeeze Scenario (25% probability if squeeze occurs)**: - **Target range: $8.00 - $12.00** (285% - 475% upside) - **Duration: 1-3 trading days** - **Trigger: Multiple positive catalysts + technical breakout** **Extreme Scenario (15% probability if squeeze occurs)**: - **Target range: $15.00+** (600%+ upside) - **Duration: Intraday to 2 days** - **Trigger: Major breakthrough + perfect storm of covering** ## Historical Context and Benchmarks ### Biotech Short Squeeze Precedents Recent biotech short squeezes provide context: - **Typical magnitude: 200-500% over 1-5 days** - **Sustainability: Most gains fade within 2-4 weeks** - **Volume characteristics: 5-20x normal volume during squeeze** ### INMB-Specific Factors - **Current price: $2.08** provides low base for percentage calculations - **Market cap: ~$53 million** allows for dramatic percentage moves - **Float: 16.5 million shares** creates manageable covering requirements ## Timing and Catalyst Sequence ### Most Likely Squeeze Triggers (Next 45 Days) **Primary Catalysts**: 1. **AAIC presentation positive reception** (July 27-31) - 40% probability 2. **BTD approval announcement** (August 2025) - 25% probability 3. **Technical breakout above $3.00** - 30% probability **Secondary Triggers**: - **Social media momentum** and retail buying surge - **Options activity** creating gamma squeeze dynamics - **Institutional covering** ahead of potential positive news ## Risk Management Considerations ### If You're Long INMB - **Profit-taking strategy**: Consider selling 25-50% of position if price reaches $4.50-$5.00 - **Stop-loss management**: Trail stops to protect gains during squeeze - **Volume monitoring**: Extreme volume (>10M shares) often marks squeeze peak ### Short Squeeze Sustainability **Historical pattern**: Most biotech short squeezes are **not sustainable**, with prices often returning to pre-squeeze levels within 2-4 weeks unless fundamental improvements materialize. ## Conclusion INMB presents a **compelling short squeeze setup** with 35-45% probability of occurrence. The combination of extreme short interest (25-38% of float), zero borrowable shares, and upcoming catalysts creates conditions similar to historical short squeeze events. **Expected magnitude**: 200-600% price appreciation over 1-5 trading days if squeeze occurs, with conservative targets of $4.50-$6.50 representing the most likely scenario. **Key insight**: The high probability reflects technical setup rather than fundamental improvement, making any squeeze likely to be **temporary unless accompanied by genuine positive clinical/regulatory developments**. For traders, this represents a **high-risk, high-reward opportunity** requiring careful position sizing and active risk management given the binary nature of both the short squeeze potential and underlying biotech catalysts.
# INMB Short Squeeze Analysis: Probability and Expected Impact Based on the comprehensive short interest data and current market dynamics, **INMB has a moderate-to-high probability (35-45%) of experiencing a short squeeze within the next 30-45 days**, with potentially dramatic price movements if it occurs. ## Current Short Interest Dynamics ### Extreme Short Interest Metrics Your IBKR screenshot reveals critical short squeeze indicators: - **Shortable shares: 0** - No shares available to borrow for new short positions - **Borrow rate: 46.1%** - Exceptionally high cost to maintain short positions - **Rate volatility: 97.4% to 10.2%** - Extreme fluctuation in borrowing costs over the past month ### Institutional Data Confirmation Multiple sources confirm heavy short positioning: - **Short interest: 5.83 million shares (25.37% of float)**[1] - **Days to cover: 20.8 days** - indicating it would take over 20 trading days to cover all short positions[1] - **Alternative measurements show up to 38.48% short float**[2] ## Short Squeeze Probability Assessment: 35-45% ### Supporting Factors (Increasing Probability) **Technical Setup (High Impact)**: - **Zero borrowable shares** creates supply constraint for new shorts - **46% borrow rate** puts severe financial pressure on existing short positions - **20.8 days to cover** suggests significant time needed for orderly covering **Fundamental Catalysts (Medium-High Impact)**: - **AAIC presentation (July 27-31)** could provide positive subgroup data - **BTD filing response** expected within 60 days - **Market oversold conditions** after 61% weekly decline may attract contrarian buyers **Market Structure (Medium Impact)**: - **Small float** (16.5M shares) amplifies impact of covering[3] - **High retail interest** evident from social media and trading volume - **Biotech sector** historically prone to sentiment-driven squeezes ### Limiting Factors (Decreasing Probability) **Recent Negative Catalyst**: - **Phase 2 primary endpoint miss** provides fundamental justification for short positions - **Multiple analyst downgrades** with targets as low as $0.60 - **Continued bearish sentiment** may attract additional short interest despite high costs **Market Environment**: - **Biotech sector challenges** with limited funding and regulatory uncertainty - **Risk-off sentiment** may limit speculative buying needed to trigger squeeze ## Expected Impact If Short Squeeze Occurs ### Price Target Analysis **Conservative Squeeze Scenario (60% probability if squeeze occurs)**: - **Target range: $4.50 - $6.50** (115% - 210% upside) - **Duration: 2-5 trading days** - **Trigger: Positive AAIC data or BTD approval** **Aggressive Squeeze Scenario (25% probability if squeeze occurs)**: - **Target range: $8.00 - $12.00** (285% - 475% upside) - **Duration: 1-3 trading days** - **Trigger: Multiple positive catalysts + technical breakout** **Extreme Scenario (15% probability if squeeze occurs)**: - **Target range: $15.00+** (600%+ upside) - **Duration: Intraday to 2 days** - **Trigger: Major breakthrough + perfect storm of covering** ## Historical Context and Benchmarks ### Biotech Short Squeeze Precedents Recent biotech short squeezes provide context: - **Typical magnitude: 200-500% over 1-5 days** - **Sustainability: Most gains fade within 2-4 weeks** - **Volume characteristics: 5-20x normal volume during squeeze** ### INMB-Specific Factors - **Current price: $2.08** provides low base for percentage calculations - **Market cap: ~$53 million** allows for dramatic percentage moves - **Float: 16.5 million shares** creates manageable covering requirements ## Timing and Catalyst Sequence ### Most Likely Squeeze Triggers (Next 45 Days) **Primary Catalysts**: 1. **AAIC presentation positive reception** (July 27-31) - 40% probability 2. **BTD approval announcement** (August 2025) - 25% probability 3. **Technical breakout above $3.00** - 30% probability **Secondary Triggers**: - **Social media momentum** and retail buying surge - **Options activity** creating gamma squeeze dynamics - **Institutional covering** ahead of potential positive news ## Risk Management Considerations ### If You're Long INMB - **Profit-taking strategy**: Consider selling 25-50% of position if price reaches $4.50-$5.00 - **Stop-loss management**: Trail stops to protect gains during squeeze - **Volume monitoring**: Extreme volume (>10M shares) often marks squeeze peak ### Short Squeeze Sustainability **Historical pattern**: Most biotech short squeezes are **not sustainable**, with prices often returning to pre-squeeze levels within 2-4 weeks unless fundamental improvements materialize. ## Conclusion INMB presents a **compelling short squeeze setup** with 35-45% probability of occurrence. The combination of extreme short interest (25-38% of float), zero borrowable shares, and upcoming catalysts creates conditions similar to historical short squeeze events. **Expected magnitude**: 200-600% price appreciation over 1-5 trading days if squeeze occurs, with conservative targets of $4.50-$6.50 representing the most likely scenario. **Key insight**: The high probability reflects technical setup rather than fundamental improvement, making any squeeze likely to be **temporary unless accompanied by genuine positive clinical/regulatory developments**. For traders, this represents a **high-risk, high-reward opportunity** requiring careful position sizing and active risk management given the binary nature of both the short squeeze potential and underlying biotech catalysts.
# INMB Short Squeeze Analysis: Probability and Expected Impact Based on the comprehensive short interest data and current market dynamics, **INMB has a moderate-to-high probability (35-45%) of experiencing a short squeeze within the next 30-45 days**, with potentially dramatic price movements if it occurs. ## Current Short Interest Dynamics ### Extreme Short Interest Metrics Your IBKR screenshot reveals critical short squeeze indicators: - **Shortable shares: 0** - No shares available to borrow for new short positions - **Borrow rate: 46.1%** - Exceptionally high cost to maintain short positions - **Rate volatility: 97.4% to 10.2%** - Extreme fluctuation in borrowing costs over the past month ### Institutional Data Confirmation Multiple sources confirm heavy short positioning: - **Short interest: 5.83 million shares (25.37% of float)**[1] - **Days to cover: 20.8 days** - indicating it would take over 20 trading days to cover all short positions[1] - **Alternative measurements show up to 38.48% short float**[2] ## Short Squeeze Probability Assessment: 35-45% ### Supporting Factors (Increasing Probability) **Technical Setup (High Impact)**: - **Zero borrowable shares** creates supply constraint for new shorts - **46% borrow rate** puts severe financial pressure on existing short positions - **20.8 days to cover** suggests significant time needed for orderly covering **Fundamental Catalysts (Medium-High Impact)**: - **AAIC presentation (July 27-31)** could provide positive subgroup data - **BTD filing response** expected within 60 days - **Market oversold conditions** after 61% weekly decline may attract contrarian buyers **Market Structure (Medium Impact)**: - **Small float** (16.5M shares) amplifies impact of covering[3] - **High retail interest** evident from social media and trading volume - **Biotech sector** historically prone to sentiment-driven squeezes ### Limiting Factors (Decreasing Probability) **Recent Negative Catalyst**: - **Phase 2 primary endpoint miss** provides fundamental justification for short positions - **Multiple analyst downgrades** with targets as low as $0.60 - **Continued bearish sentiment** may attract additional short interest despite high costs **Market Environment**: - **Biotech sector challenges** with limited funding and regulatory uncertainty - **Risk-off sentiment** may limit speculative buying needed to trigger squeeze ## Expected Impact If Short Squeeze Occurs ### Price Target Analysis **Conservative Squeeze Scenario (60% probability if squeeze occurs)**: - **Target range: $4.50 - $6.50** (115% - 210% upside) - **Duration: 2-5 trading days** - **Trigger: Positive AAIC data or BTD approval** **Aggressive Squeeze Scenario (25% probability if squeeze occurs)**: - **Target range: $8.00 - $12.00** (285% - 475% upside) - **Duration: 1-3 trading days** - **Trigger: Multiple positive catalysts + technical breakout** **Extreme Scenario (15% probability if squeeze occurs)**: - **Target range: $15.00+** (600%+ upside) - **Duration: Intraday to 2 days** - **Trigger: Major breakthrough + perfect storm of covering** ## Historical Context and Benchmarks ### Biotech Short Squeeze Precedents Recent biotech short squeezes provide context: - **Typical magnitude: 200-500% over 1-5 days** - **Sustainability: Most gains fade within 2-4 weeks** - **Volume characteristics: 5-20x normal volume during squeeze** ### INMB-Specific Factors - **Current price: $2.08** provides low base for percentage calculations - **Market cap: ~$53 million** allows for dramatic percentage moves - **Float: 16.5 million shares** creates manageable covering requirements ## Timing and Catalyst Sequence ### Most Likely Squeeze Triggers (Next 45 Days) **Primary Catalysts**: 1. **AAIC presentation positive reception** (July 27-31) - 40% probability 2. **BTD approval announcement** (August 2025) - 25% probability 3. **Technical breakout above $3.00** - 30% probability **Secondary Triggers**: - **Social media momentum** and retail buying surge - **Options activity** creating gamma squeeze dynamics - **Institutional covering** ahead of potential positive news ## Risk Management Considerations ### If You're Long INMB - **Profit-taking strategy**: Consider selling 25-50% of position if price reaches $4.50-$5.00 - **Stop-loss management**: Trail stops to protect gains during squeeze - **Volume monitoring**: Extreme volume (>10M shares) often marks squeeze peak ### Short Squeeze Sustainability **Historical pattern**: Most biotech short squeezes are **not sustainable**, with prices often returning to pre-squeeze levels within 2-4 weeks unless fundamental improvements materialize. ## Conclusion INMB presents a **compelling short squeeze setup** with 35-45% probability of occurrence. The combination of extreme short interest (25-38% of float), zero borrowable shares, and upcoming catalysts creates conditions similar to historical short squeeze events. **Expected magnitude**: 200-600% price appreciation over 1-5 trading days if squeeze occurs, with conservative targets of $4.50-$6.50 representing the most likely scenario. **Key insight**: The high probability reflects technical setup rather than fundamental improvement, making any squeeze likely to be **temporary unless accompanied by genuine positive clinical/regulatory developments**. For traders, this represents a **high-risk, high-reward opportunity** requiring careful position sizing and active risk management given the binary nature of both the short squeeze potential and underlying biotech catalysts.
# INMB Short Squeeze Analysis: Probability and Expected Impact Based on the comprehensive short interest data and current market dynamics, **INMB has a moderate-to-high probability (35-45%) of experiencing a short squeeze within the next 30-45 days**, with potentially dramatic price movements if it occurs. ## Current Short Interest Dynamics ### Extreme Short Interest Metrics Your IBKR screenshot reveals critical short squeeze indicators: - **Shortable shares: 0** - No shares available to borrow for new short positions - **Borrow rate: 46.1%** - Exceptionally high cost to maintain short positions - **Rate volatility: 97.4% to 10.2%** - Extreme fluctuation in borrowing costs over the past month ### Institutional Data Confirmation Multiple sources confirm heavy short positioning: - **Short interest: 5.83 million shares (25.37% of float)**[1] - **Days to cover: 20.8 days** - indicating it would take over 20 trading days to cover all short positions[1] - **Alternative measurements show up to 38.48% short float**[2] ## Short Squeeze Probability Assessment: 35-45% ### Supporting Factors (Increasing Probability) **Technical Setup (High Impact)**: - **Zero borrowable shares** creates supply constraint for new shorts - **46% borrow rate** puts severe financial pressure on existing short positions - **20.8 days to cover** suggests significant time needed for orderly covering **Fundamental Catalysts (Medium-High Impact)**: - **AAIC presentation (July 27-31)** could provide positive subgroup data - **BTD filing response** expected within 60 days - **Market oversold conditions** after 61% weekly decline may attract contrarian buyers **Market Structure (Medium Impact)**: - **Small float** (16.5M shares) amplifies impact of covering[3] - **High retail interest** evident from social media and trading volume - **Biotech sector** historically prone to sentiment-driven squeezes ### Limiting Factors (Decreasing Probability) **Recent Negative Catalyst**: - **Phase 2 primary endpoint miss** provides fundamental justification for short positions - **Multiple analyst downgrades** with targets as low as $0.60 - **Continued bearish sentiment** may attract additional short interest despite high costs **Market Environment**: - **Biotech sector challenges** with limited funding and regulatory uncertainty - **Risk-off sentiment** may limit speculative buying needed to trigger squeeze ## Expected Impact If Short Squeeze Occurs ### Price Target Analysis **Conservative Squeeze Scenario (60% probability if squeeze occurs)**: - **Target range: $4.50 - $6.50** (115% - 210% upside) - **Duration: 2-5 trading days** - **Trigger: Positive AAIC data or BTD approval** **Aggressive Squeeze Scenario (25% probability if squeeze occurs)**: - **Target range: $8.00 - $12.00** (285% - 475% upside) - **Duration: 1-3 trading days** - **Trigger: Multiple positive catalysts + technical breakout** **Extreme Scenario (15% probability if squeeze occurs)**: - **Target range: $15.00+** (600%+ upside) - **Duration: Intraday to 2 days** - **Trigger: Major breakthrough + perfect storm of covering** ## Historical Context and Benchmarks ### Biotech Short Squeeze Precedents Recent biotech short squeezes provide context: - **Typical magnitude: 200-500% over 1-5 days** - **Sustainability: Most gains fade within 2-4 weeks** - **Volume characteristics: 5-20x normal volume during squeeze** ### INMB-Specific Factors - **Current price: $2.08** provides low base for percentage calculations - **Market cap: ~$53 million** allows for dramatic percentage moves - **Float: 16.5 million shares** creates manageable covering requirements ## Timing and Catalyst Sequence ### Most Likely Squeeze Triggers (Next 45 Days) **Primary Catalysts**: 1. **AAIC presentation positive reception** (July 27-31) - 40% probability 2. **BTD approval announcement** (August 2025) - 25% probability 3. **Technical breakout above $3.00** - 30% probability **Secondary Triggers**: - **Social media momentum** and retail buying surge - **Options activity** creating gamma squeeze dynamics - **Institutional covering** ahead of potential positive news ## Risk Management Considerations ### If You're Long INMB - **Profit-taking strategy**: Consider selling 25-50% of position if price reaches $4.50-$5.00 - **Stop-loss management**: Trail stops to protect gains during squeeze - **Volume monitoring**: Extreme volume (>10M shares) often marks squeeze peak ### Short Squeeze Sustainability **Historical pattern**: Most biotech short squeezes are **not sustainable**, with prices often returning to pre-squeeze levels within 2-4 weeks unless fundamental improvements materialize. ## Conclusion INMB presents a **compelling short squeeze setup** with 35-45% probability of occurrence. The combination of extreme short interest (25-38% of float), zero borrowable shares, and upcoming catalysts creates conditions similar to historical short squeeze events. **Expected magnitude**: 200-600% price appreciation over 1-5 trading days if squeeze occurs, with conservative targets of $4.50-$6.50 representing the most likely scenario. **Key insight**: The high probability reflects technical setup rather than fundamental improvement, making any squeeze likely to be **temporary unless accompanied by genuine positive clinical/regulatory developments**. For traders, this represents a **high-risk, high-reward opportunity** requiring careful position sizing and active risk management given the binary nature of both the short squeeze potential and underlying biotech catalysts.
# INMB Short Squeeze Analysis: Probability and Expected Impact Based on the comprehensive short interest data and current market dynamics, **INMB has a moderate-to-high probability (35-45%) of experiencing a short squeeze within the next 30-45 days**, with potentially dramatic price movements if it occurs. ## Current Short Interest Dynamics ### Extreme Short Interest Metrics Your IBKR screenshot reveals critical short squeeze indicators: - **Shortable shares: 0** - No shares available to borrow for new short positions - **Borrow rate: 46.1%** - Exceptionally high cost to maintain short positions - **Rate volatility: 97.4% to 10.2%** - Extreme fluctuation in borrowing costs over the past month ### Institutional Data Confirmation Multiple sources confirm heavy short positioning: - **Short interest: 5.83 million shares (25.37% of float)**[1] - **Days to cover: 20.8 days** - indicating it would take over 20 trading days to cover all short positions[1] - **Alternative measurements show up to 38.48% short float**[2] ## Short Squeeze Probability Assessment: 35-45% ### Supporting Factors (Increasing Probability) **Technical Setup (High Impact)**: - **Zero borrowable shares** creates supply constraint for new shorts - **46% borrow rate** puts severe financial pressure on existing short positions - **20.8 days to cover** suggests significant time needed for orderly covering **Fundamental Catalysts (Medium-High Impact)**: - **AAIC presentation (July 27-31)** could provide positive subgroup data - **BTD filing response** expected within 60 days - **Market oversold conditions** after 61% weekly decline may attract contrarian buyers **Market Structure (Medium Impact)**: - **Small float** (16.5M shares) amplifies impact of covering[3] - **High retail interest** evident from social media and trading volume - **Biotech sector** historically prone to sentiment-driven squeezes ### Limiting Factors (Decreasing Probability) **Recent Negative Catalyst**: - **Phase 2 primary endpoint miss** provides fundamental justification for short positions - **Multiple analyst downgrades** with targets as low as $0.60 - **Continued bearish sentiment** may attract additional short interest despite high costs **Market Environment**: - **Biotech sector challenges** with limited funding and regulatory uncertainty - **Risk-off sentiment** may limit speculative buying needed to trigger squeeze ## Expected Impact If Short Squeeze Occurs ### Price Target Analysis **Conservative Squeeze Scenario (60% probability if squeeze occurs)**: - **Target range: $4.50 - $6.50** (115% - 210% upside) - **Duration: 2-5 trading days** - **Trigger: Positive AAIC data or BTD approval** **Aggressive Squeeze Scenario (25% probability if squeeze occurs)**: - **Target range: $8.00 - $12.00** (285% - 475% upside) - **Duration: 1-3 trading days** - **Trigger: Multiple positive catalysts + technical breakout** **Extreme Scenario (15% probability if squeeze occurs)**: - **Target range: $15.00+** (600%+ upside) - **Duration: Intraday to 2 days** - **Trigger: Major breakthrough + perfect storm of covering** ## Historical Context and Benchmarks ### Biotech Short Squeeze Precedents Recent biotech short squeezes provide context: - **Typical magnitude: 200-500% over 1-5 days** - **Sustainability: Most gains fade within 2-4 weeks** - **Volume characteristics: 5-20x normal volume during squeeze** ### INMB-Specific Factors - **Current price: $2.08** provides low base for percentage calculations - **Market cap: ~$53 million** allows for dramatic percentage moves - **Float: 16.5 million shares** creates manageable covering requirements ## Timing and Catalyst Sequence ### Most Likely Squeeze Triggers (Next 45 Days) **Primary Catalysts**: 1. **AAIC presentation positive reception** (July 27-31) - 40% probability 2. **BTD approval announcement** (August 2025) - 25% probability 3. **Technical breakout above $3.00** - 30% probability **Secondary Triggers**: - **Social media momentum** and retail buying surge - **Options activity** creating gamma squeeze dynamics - **Institutional covering** ahead of potential positive news ## Risk Management Considerations ### If You're Long INMB - **Profit-taking strategy**: Consider selling 25-50% of position if price reaches $4.50-$5.00 - **Stop-loss management**: Trail stops to protect gains during squeeze - **Volume monitoring**: Extreme volume (>10M shares) often marks squeeze peak ### Short Squeeze Sustainability **Historical pattern**: Most biotech short squeezes are **not sustainable**, with prices often returning to pre-squeeze levels within 2-4 weeks unless fundamental improvements materialize. ## Conclusion INMB presents a **compelling short squeeze setup** with 35-45% probability of occurrence. The combination of extreme short interest (25-38% of float), zero borrowable shares, and upcoming catalysts creates conditions similar to historical short squeeze events. **Expected magnitude**: 200-600% price appreciation over 1-5 trading days if squeeze occurs, with conservative targets of $4.50-$6.50 representing the most likely scenario. **Key insight**: The high probability reflects technical setup rather than fundamental improvement, making any squeeze likely to be **temporary unless accompanied by genuine positive clinical/regulatory developments**. For traders, this represents a **high-risk, high-reward opportunity** requiring careful position sizing and active risk management given the binary nature of both the short squeeze potential and underlying biotech catalysts.
# INMB Short Squeeze Analysis: Probability and Expected Impact Based on the comprehensive short interest data and current market dynamics, **INMB has a moderate-to-high probability (35-45%) of experiencing a short squeeze within the next 30-45 days**, with potentially dramatic price movements if it occurs. ## Current Short Interest Dynamics ### Extreme Short Interest Metrics Your IBKR screenshot reveals critical short squeeze indicators: - **Shortable shares: 0** - No shares available to borrow for new short positions - **Borrow rate: 46.1%** - Exceptionally high cost to maintain short positions - **Rate volatility: 97.4% to 10.2%** - Extreme fluctuation in borrowing costs over the past month ### Institutional Data Confirmation Multiple sources confirm heavy short positioning: - **Short interest: 5.83 million shares (25.37% of float)**[1] - **Days to cover: 20.8 days** - indicating it would take over 20 trading days to cover all short positions[1] - **Alternative measurements show up to 38.48% short float**[2] ## Short Squeeze Probability Assessment: 35-45% ### Supporting Factors (Increasing Probability) **Technical Setup (High Impact)**: - **Zero borrowable shares** creates supply constraint for new shorts - **46% borrow rate** puts severe financial pressure on existing short positions - **20.8 days to cover** suggests significant time needed for orderly covering **Fundamental Catalysts (Medium-High Impact)**: - **AAIC presentation (July 27-31)** could provide positive subgroup data - **BTD filing response** expected within 60 days - **Market oversold conditions** after 61% weekly decline may attract contrarian buyers **Market Structure (Medium Impact)**: - **Small float** (16.5M shares) amplifies impact of covering[3] - **High retail interest** evident from social media and trading volume - **Biotech sector** historically prone to sentiment-driven squeezes ### Limiting Factors (Decreasing Probability) **Recent Negative Catalyst**: - **Phase 2 primary endpoint miss** provides fundamental justification for short positions - **Multiple analyst downgrades** with targets as low as $0.60 - **Continued bearish sentiment** may attract additional short interest despite high costs **Market Environment**: - **Biotech sector challenges** with limited funding and regulatory uncertainty - **Risk-off sentiment** may limit speculative buying needed to trigger squeeze ## Expected Impact If Short Squeeze Occurs ### Price Target Analysis **Conservative Squeeze Scenario (60% probability if squeeze occurs)**: - **Target range: $4.50 - $6.50** (115% - 210% upside) - **Duration: 2-5 trading days** - **Trigger: Positive AAIC data or BTD approval** **Aggressive Squeeze Scenario (25% probability if squeeze occurs)**: - **Target range: $8.00 - $12.00** (285% - 475% upside) - **Duration: 1-3 trading days** - **Trigger: Multiple positive catalysts + technical breakout** **Extreme Scenario (15% probability if squeeze occurs)**: - **Target range: $15.00+** (600%+ upside) - **Duration: Intraday to 2 days** - **Trigger: Major breakthrough + perfect storm of covering** ## Historical Context and Benchmarks ### Biotech Short Squeeze Precedents Recent biotech short squeezes provide context: - **Typical magnitude: 200-500% over 1-5 days** - **Sustainability: Most gains fade within 2-4 weeks** - **Volume characteristics: 5-20x normal volume during squeeze** ### INMB-Specific Factors - **Current price: $2.08** provides low base for percentage calculations - **Market cap: ~$53 million** allows for dramatic percentage moves - **Float: 16.5 million shares** creates manageable covering requirements ## Timing and Catalyst Sequence ### Most Likely Squeeze Triggers (Next 45 Days) **Primary Catalysts**: 1. **AAIC presentation positive reception** (July 27-31) - 40% probability 2. **BTD approval announcement** (August 2025) - 25% probability 3. **Technical breakout above $3.00** - 30% probability **Secondary Triggers**: - **Social media momentum** and retail buying surge - **Options activity** creating gamma squeeze dynamics - **Institutional covering** ahead of potential positive news ## Risk Management Considerations ### If You're Long INMB - **Profit-taking strategy**: Consider selling 25-50% of position if price reaches $4.50-$5.00 - **Stop-loss management**: Trail stops to protect gains during squeeze - **Volume monitoring**: Extreme volume (>10M shares) often marks squeeze peak ### Short Squeeze Sustainability **Historical pattern**: Most biotech short squeezes are **not sustainable**, with prices often returning to pre-squeeze levels within 2-4 weeks unless fundamental improvements materialize. ## Conclusion INMB presents a **compelling short squeeze setup** with 35-45% probability of occurrence. The combination of extreme short interest (25-38% of float), zero borrowable shares, and upcoming catalysts creates conditions similar to historical short squeeze events. **Expected magnitude**: 200-600% price appreciation over 1-5 trading days if squeeze occurs, with conservative targets of $4.50-$6.50 representing the most likely scenario. **Key insight**: The high probability reflects technical setup rather than fundamental improvement, making any squeeze likely to be **temporary unless accompanied by genuine positive clinical/regulatory developments**. For traders, this represents a **high-risk, high-reward opportunity** requiring careful position sizing and active risk management given the binary nature of both the short squeeze potential and underlying biotech catalysts.
# INMB Short Squeeze Analysis: Probability and Expected Impact Based on the comprehensive short interest data and current market dynamics, **INMB has a moderate-to-high probability (35-45%) of experiencing a short squeeze within the next 30-45 days**, with potentially dramatic price movements if it occurs. ## Current Short Interest Dynamics ### Extreme Short Interest Metrics Your IBKR screenshot reveals critical short squeeze indicators: - **Shortable shares: 0** - No shares available to borrow for new short positions - **Borrow rate: 46.1%** - Exceptionally high cost to maintain short positions - **Rate volatility: 97.4% to 10.2%** - Extreme fluctuation in borrowing costs over the past month ### Institutional Data Confirmation Multiple sources confirm heavy short positioning: - **Short interest: 5.83 million shares (25.37% of float)**[1] - **Days to cover: 20.8 days** - indicating it would take over 20 trading days to cover all short positions[1] - **Alternative measurements show up to 38.48% short float**[2] ## Short Squeeze Probability Assessment: 35-45% ### Supporting Factors (Increasing Probability) **Technical Setup (High Impact)**: - **Zero borrowable shares** creates supply constraint for new shorts - **46% borrow rate** puts severe financial pressure on existing short positions - **20.8 days to cover** suggests significant time needed for orderly covering **Fundamental Catalysts (Medium-High Impact)**: - **AAIC presentation (July 27-31)** could provide positive subgroup data - **BTD filing response** expected within 60 days - **Market oversold conditions** after 61% weekly decline may attract contrarian buyers **Market Structure (Medium Impact)**: - **Small float** (16.5M shares) amplifies impact of covering[3] - **High retail interest** evident from social media and trading volume - **Biotech sector** historically prone to sentiment-driven squeezes ### Limiting Factors (Decreasing Probability) **Recent Negative Catalyst**: - **Phase 2 primary endpoint miss** provides fundamental justification for short positions - **Multiple analyst downgrades** with targets as low as $0.60 - **Continued bearish sentiment** may attract additional short interest despite high costs **Market Environment**: - **Biotech sector challenges** with limited funding and regulatory uncertainty - **Risk-off sentiment** may limit speculative buying needed to trigger squeeze ## Expected Impact If Short Squeeze Occurs ### Price Target Analysis **Conservative Squeeze Scenario (60% probability if squeeze occurs)**: - **Target range: $4.50 - $6.50** (115% - 210% upside) - **Duration: 2-5 trading days** - **Trigger: Positive AAIC data or BTD approval** **Aggressive Squeeze Scenario (25% probability if squeeze occurs)**: - **Target range: $8.00 - $12.00** (285% - 475% upside) - **Duration: 1-3 trading days** - **Trigger: Multiple positive catalysts + technical breakout** **Extreme Scenario (15% probability if squeeze occurs)**: - **Target range: $15.00+** (600%+ upside) - **Duration: Intraday to 2 days** - **Trigger: Major breakthrough + perfect storm of covering** ## Historical Context and Benchmarks ### Biotech Short Squeeze Precedents Recent biotech short squeezes provide context: - **Typical magnitude: 200-500% over 1-5 days** - **Sustainability: Most gains fade within 2-4 weeks** - **Volume characteristics: 5-20x normal volume during squeeze** ### INMB-Specific Factors - **Current price: $2.08** provides low base for percentage calculations - **Market cap: ~$53 million** allows for dramatic percentage moves - **Float: 16.5 million shares** creates manageable covering requirements ## Timing and Catalyst Sequence ### Most Likely Squeeze Triggers (Next 45 Days) **Primary Catalysts**: 1. **AAIC presentation positive reception** (July 27-31) - 40% probability 2. **BTD approval announcement** (August 2025) - 25% probability 3. **Technical breakout above $3.00** - 30% probability **Secondary Triggers**: - **Social media momentum** and retail buying surge - **Options activity** creating gamma squeeze dynamics - **Institutional covering** ahead of potential positive news ## Risk Management Considerations ### If You're Long INMB - **Profit-taking strategy**: Consider selling 25-50% of position if price reaches $4.50-$5.00 - **Stop-loss management**: Trail stops to protect gains during squeeze - **Volume monitoring**: Extreme volume (>10M shares) often marks squeeze peak ### Short Squeeze Sustainability **Historical pattern**: Most biotech short squeezes are **not sustainable**, with prices often returning to pre-squeeze levels within 2-4 weeks unless fundamental improvements materialize. ## Conclusion INMB presents a **compelling short squeeze setup** with 35-45% probability of occurrence. The combination of extreme short interest (25-38% of float), zero borrowable shares, and upcoming catalysts creates conditions similar to historical short squeeze events. **Expected magnitude**: 200-600% price appreciation over 1-5 trading days if squeeze occurs, with conservative targets of $4.50-$6.50 representing the most likely scenario. **Key insight**: The high probability reflects technical setup rather than fundamental improvement, making any squeeze likely to be **temporary unless accompanied by genuine positive clinical/regulatory developments**. For traders, this represents a **high-risk, high-reward opportunity** requiring careful position sizing and active risk management given the binary nature of both the short squeeze potential and underlying biotech catalysts.
# INMB Short Squeeze Analysis: Probability and Expected Impact Based on the comprehensive short interest data and current market dynamics, **INMB has a moderate-to-high probability (35-45%) of experiencing a short squeeze within the next 30-45 days**, with potentially dramatic price movements if it occurs. ## Current Short Interest Dynamics ### Extreme Short Interest Metrics Your IBKR screenshot reveals critical short squeeze indicators: - **Shortable shares: 0** - No shares available to borrow for new short positions - **Borrow rate: 46.1%** - Exceptionally high cost to maintain short positions - **Rate volatility: 97.4% to 10.2%** - Extreme fluctuation in borrowing costs over the past month ### Institutional Data Confirmation Multiple sources confirm heavy short positioning: - **Short interest: 5.83 million shares (25.37% of float)**[1] - **Days to cover: 20.8 days** - indicating it would take over 20 trading days to cover all short positions[1] - **Alternative measurements show up to 38.48% short float**[2] ## Short Squeeze Probability Assessment: 35-45% ### Supporting Factors (Increasing Probability) **Technical Setup (High Impact)**: - **Zero borrowable shares** creates supply constraint for new shorts - **46% borrow rate** puts severe financial pressure on existing short positions - **20.8 days to cover** suggests significant time needed for orderly covering **Fundamental Catalysts (Medium-High Impact)**: - **AAIC presentation (July 27-31)** could provide positive subgroup data - **BTD filing response** expected within 60 days - **Market oversold conditions** after 61% weekly decline may attract contrarian buyers **Market Structure (Medium Impact)**: - **Small float** (16.5M shares) amplifies impact of covering[3] - **High retail interest** evident from social media and trading volume - **Biotech sector** historically prone to sentiment-driven squeezes ### Limiting Factors (Decreasing Probability) **Recent Negative Catalyst**: - **Phase 2 primary endpoint miss** provides fundamental justification for short positions - **Multiple analyst downgrades** with targets as low as $0.60 - **Continued bearish sentiment** may attract additional short interest despite high costs **Market Environment**: - **Biotech sector challenges** with limited funding and regulatory uncertainty - **Risk-off sentiment** may limit speculative buying needed to trigger squeeze ## Expected Impact If Short Squeeze Occurs ### Price Target Analysis **Conservative Squeeze Scenario (60% probability if squeeze occurs)**: - **Target range: $4.50 - $6.50** (115% - 210% upside) - **Duration: 2-5 trading days** - **Trigger: Positive AAIC data or BTD approval** **Aggressive Squeeze Scenario (25% probability if squeeze occurs)**: - **Target range: $8.00 - $12.00** (285% - 475% upside) - **Duration: 1-3 trading days** - **Trigger: Multiple positive catalysts + technical breakout** **Extreme Scenario (15% probability if squeeze occurs)**: - **Target range: $15.00+** (600%+ upside) - **Duration: Intraday to 2 days** - **Trigger: Major breakthrough + perfect storm of covering** ## Historical Context and Benchmarks ### Biotech Short Squeeze Precedents Recent biotech short squeezes provide context: - **Typical magnitude: 200-500% over 1-5 days** - **Sustainability: Most gains fade within 2-4 weeks** - **Volume characteristics: 5-20x normal volume during squeeze** ### INMB-Specific Factors - **Current price: $2.08** provides low base for percentage calculations - **Market cap: ~$53 million** allows for dramatic percentage moves - **Float: 16.5 million shares** creates manageable covering requirements ## Timing and Catalyst Sequence ### Most Likely Squeeze Triggers (Next 45 Days) **Primary Catalysts**: 1. **AAIC presentation positive reception** (July 27-31) - 40% probability 2. **BTD approval announcement** (August 2025) - 25% probability 3. **Technical breakout above $3.00** - 30% probability **Secondary Triggers**: - **Social media momentum** and retail buying surge - **Options activity** creating gamma squeeze dynamics - **Institutional covering** ahead of potential positive news ## Risk Management Considerations ### If You're Long INMB - **Profit-taking strategy**: Consider selling 25-50% of position if price reaches $4.50-$5.00 - **Stop-loss management**: Trail stops to protect gains during squeeze - **Volume monitoring**: Extreme volume (>10M shares) often marks squeeze peak ### Short Squeeze Sustainability **Historical pattern**: Most biotech short squeezes are **not sustainable**, with prices often returning to pre-squeeze levels within 2-4 weeks unless fundamental improvements materialize. ## Conclusion INMB presents a **compelling short squeeze setup** with 35-45% probability of occurrence. The combination of extreme short interest (25-38% of float), zero borrowable shares, and upcoming catalysts creates conditions similar to historical short squeeze events. **Expected magnitude**: 200-600% price appreciation over 1-5 trading days if squeeze occurs, with conservative targets of $4.50-$6.50 representing the most likely scenario. **Key insight**: The high probability reflects technical setup rather than fundamental improvement, making any squeeze likely to be **temporary unless accompanied by genuine positive clinical/regulatory developments**. For traders, this represents a **high-risk, high-reward opportunity** requiring careful position sizing and active risk management given the binary nature of both the short squeeze potential and underlying biotech catalysts.
INMB was such an easy short. Thank you Martin.
The data is available on their website ahead of the call - https://www.inmunebio.com/images/pdf/presentation/2025/INMB_Website_July_2025_For_Release_6.29.25_v2.FINAL.pdf
I think they accidentally leaked the presentation early - https://www.inmunebio.com/images/pdf/presentation/2025/INMB_Website_July_2025_For_Release_6.29.25_v2.FINAL.pdf
**Another point** ahead of top line trial data being released tomorrow morning: **Short Ratio of 16 is extremely high** — traders are betting hard against INMB ahead of June 30. **This sets up a potential short squeeze** if trial results beat expectations. The rest of the stock’s profile (low float, oversold, undervalued) adds fuel to the fire. Combine that with a breakthrough Alzheimer’s drug, and this becomes a rare asymmetric biotech setup. If the science is real the **people shorting this stock may soon be** ***forced buyers***. That’s when fireworks happen. 💥
tried to buy puts on INMB when it was at $10. 10p's were $5.00, after it dumped down to $5.50, 10p's were $6. this is why biotech puts are hard to play.
I wish they disclosed the companies that invested, we'll find out soon enough but still. I also wonder, if the data is good, why would INMB agree to 6.30? Makes me think IMNB's data isn't great.
Everyone at $INMB going to jail lmao holy shit
INMB announced they are issuing 3 million shares at 6.30 each.
INMB. Ouch. Put in a very small position but it has already had its run. Have you seen more success with the AI list over the non-AI? I saw your recent post setting out your overall gains from using SF. Do they help you establish good opening and exit positions?
INMB offering; [https://www.stocktitan.net/news/INMB/i-nmune-bio-inc-announces-approximately-19-million-registered-direct-rlxw6yilb73y.html](https://www.stocktitan.net/news/INMB/i-nmune-bio-inc-announces-approximately-19-million-registered-direct-rlxw6yilb73y.html)
How long is the runway on this? Also any thoughts on INMB - I bought in pre monday report on their alzheimer’s study data
anyone shorting INMB after this spike this morning?
SAVA announced on a Sunday a webcast the following day at 8am to present P3 topline data, giving no time to market participants (understandably) INMB PRs yesterday for a webcast on Monday (4 days later), making sure this gives sufficient time for anyone who has not yet done their DD to get up to speed, and also giving the opportunity to get as much news coverage ahead of the webcast and get all the spotlight... I really wonder why 🤔
INMB 🚀 soon $20 https://preview.redd.it/lamy99y4of9f1.jpeg?width=1170&format=pjpg&auto=webp&s=ac1310c1813d1e4e2d45a1b6ee19c8141489631f
someone call make a house call to shkreli, make sure hes ok . INMB up 70% AH. thats strike 3 for him. quantum, srpt, inmb.
i can't see the linked comment; anyhow, im long INMB (only $1k value tho & up 80% rn). is the only reason for the pump because they announced that they are announcing data on monday?
[I called it on $INMB](https://www.reddit.com/r/wallstreetbets/comments/1lg0ptb/daily_discussion_thread_for_june_20_2025/myt5x4s/) Most predictable pump of all time. Short goes back on tomorrow. Let's dance.
Going all in on INMB tomorrow. Wendy's or tendies on Monday.
Thanks so much! I went more conservative. I wonder which phase INMB is on? Probably should’ve checked before I loaded up 😆
INMB, aka INmune Bio Inc, aka biotech. The premiums are justified. There, I just gave you the answer, use it as you see fit.
I wanna short INMB again before data but there's obviously going to be another pump beforehand.
I'm in! I also really believe in $BPMC for the strength and $INMB for the growth opportunity
What do you think of $BPMC and $INMB instead? Can you analyze them? I see them both as beneficial to have in your portfolio
Lucid Capital recently issued a 55-page report written by a PhD in Biochemistry with a buy recommendation. Additionally, INMB has 50 percent institutional ownership (most phase 1s have 10-30 percent) as well as very high insider ownership with a very large purchase in the last year. Very good numbers for a small cap bio. That being said a binary event is approaching. Might lose up 75% on a bad readout or go up 700% on a good one, nobody knows. Probably the most optimistic thing that can be said it is likely an asymmetrical bet. They certainly have an interesting approach. Lots of information. I most never invest in pre-approval bios but this might be an exceptional opportunity. Last time I tried was VRNA, has worked out nicely. Bet sizing is key.
INMB Phase Two results on XPRO for Alzheimer’s will be released in June. $168 M Mkt. Cap. Targets inflammation. This stops cognitive decline.
INMB guys, started to move, don’t miss the train…
INMB, penny stock status will be gone soon.. BULLISH ASF 🆙️🆙️
INMB, earnings 4:30 pm est🤑🤫
INMB-an aftermarket squeeze is a distinct possibility
INMB-🎯 KOSK-Lottery 🎟 🎫 🎟